Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Hypotensive response to debrisoquine and hydroxylation phenotype.

Idle JR, Mahgoub A, Lancaster R, Smith RL.

Life Sci. 1978 Mar;22(11):979-83. No abstract available.

PMID:
642709
2.

The disposition of debrisoquine in hypertensive patients.

Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR.

Br J Clin Pharmacol. 1978 Jan;5(1):27-34. No abstract available.

3.

Polymorphic hydroxylation of debrisoquine in Ghanaians [proceedings].

Andoh B, Idle JR, Mahgoub A, Sloan TP, Smith RL, Woolhouse N.

Br J Pharmacol. 1979 Jul;66(3):431P. No abstract available.

4.

Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.

Spina E, Buemi AL, Sanz E, Bertilsson L.

Ther Drug Monit. 1989 Nov;11(6):721-3.

PMID:
2595755
5.

Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C.

Ther Drug Monit. 1985;7(4):478-80. No abstract available.

PMID:
4082245
6.

Interethnic dissociation between debrisoquine and desipramine hydroxylation.

Rudorfer MV, Lane EA, Potter WZ.

J Clin Psychopharmacol. 1985 Apr;5(2):89-92.

PMID:
3988975
7.

Why hypertensive patients vary in their response to oral debrisoquine.

Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR.

Br Med J. 1977 Feb 12;1(6058):422-5.

8.

Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.

Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR.

Br J Clin Pharmacol. 1985 Jul;20(1):81-4.

9.
10.
11.

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F.

Life Sci. 1980 Nov 3;27(18):1673-7. No abstract available.

PMID:
7442467
12.

Polymorphic hydroxylation of debrisoquine.

Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ.

Lancet. 1977 Oct 1;2(8040):718. No abstract available.

PMID:
71525
13.

Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.

Spina E, Steiner E, Ericsson O, Sjöqvist F.

Clin Pharmacol Ther. 1987 Mar;41(3):314-9.

PMID:
3816019
14.

Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.

Alván G, Grind M, Graffner C, Sjöqvist F.

Clin Pharmacol Ther. 1984 Oct;36(4):515-9.

PMID:
6478737
15.

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F.

Clin Pharmacol Ther. 1981 Aug;30(2):189-93.

PMID:
7249504
16.

Polymorphism of debrisoquine hydroxylation among Finns and Lapps.

Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O.

Br J Clin Pharmacol. 1988 Nov;26(5):601-3.

17.

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF.

Br J Clin Pharmacol. 1984 Jun;17(6):679-85.

19.
20.

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.

Brøsen K, Gram LF, Haghfelt T, Bertilsson L.

Pharmacol Toxicol. 1987 Apr;60(4):312-4.

PMID:
3588528

Supplemental Content

Support Center